Custom assay design is your first inflection point. Are you asking the right questions?
Choosing the wrong path early costs months later
The decision happens fast. You're 6-9 months from IND. You know what you want to measure. So you look for an assay—and either force-fit something close enough, or realize nothing exists. By then, you're already behind. Today's developers are navigating:
- Novel mechanisms (cell therapy, gene therapy, advanced modalities) where standard assays don't apply
- Regulatory questions that diagnostic platforms can't answer with precision
- Pre-clinical to clinical consistency requirements that demand assay planning from day one
- Timeline pressure that makes assay validation feel like a luxury rather than infrastructure
- Lab partners who understand the science but miss the regulatory expectations baked into design
hVIVO Delivers Clarity on Custom Assay Design
This brief outlines five questions that clarify your path. It's grounded in years of working with sponsors across infectious disease, immunology, oncology, and advanced modalities. Some programmes need custom design. Others don't. But you need to know which one is yours before you commit.
One brief. Five questions that change everything.
What Specific Question Are You Trying to Answer?
Is Your Therapeutic Novel Enough That Standard Assays Don't Fit?
Cell therapy, gene therapy, ADC, novel antiviral—if you're the first to ask this question, custom development is likely necessary.
When Do You Need This Validated?
How Long Do You Need This Assay to Last?
One-off exploratory test, or infrastructure spanning pre-clinical through Phase III? This changes how you approach design.
Do You Have a Lab Partner With Multi-Platform Expertise?